The webinar will begin in:


welcome



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

Questions/concerns

patentscope@wipo.int

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

Survey 2021


2021
Olympia
TAB

Non-Patent Literature

(NPL)

Advanced search



Field Combination



Result list


IC:("A61K31/551")
25,523 results
Offices all
Languages all
Stemming true
Single Family Member false
Include NPL false
REFINE OPTIONS
Close
Search
Offices
All
Languages
All
Stemming
Single Family Member
Include NPL

Analysis


DP:2021
22,819 results
Offices all
Languages all
Stemming true
Single Family Member false
Include NPL true
ANALYSIS
Close
Filters
Charts
Timeseries
Offices
PCT 11,971
United States of America 8,258
Germany 1,244
Australia 321
Denmark 144
Spain 91
Canada 48
China 24
European Patent Office 23
Republic of Korea 12
Russian Federation 4
United Kingdom 1
Indonesia 1
Applicants
HUAWEI TECH CO LTD 313
LG ELECTRONICS INC 308
SAMSUNG ELECTRONICS CO LTD 269
MITSUBISHI ELECTRIC CO 210
QUALCOMM INC 190
MICROSOFT TECH LICENSING LLC 168
ROBERT BOSCH GMBH 151
AAC ACOUSTIC TECH (SHENZHEN) CO LTD 129
NIPPON TELEGRAPH AND TELEPHONE CO 123
GUANGDONG OPPO MOBILE TELECOMMUNICATIONS CO LTD 122
SONY CO 121
PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO LTD 120
TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) 117
HEWLETT PACKARD DEVELOPMENT COMPANY LP 110
INTERNATIONAL BUSINESS MACHINES CO 100
Inventors
TIAGO PAIVA 31
JAFAR ADIBI 30
BRUNO ANTUNES 27
CHARANYA KANNAN 27
JOAO CARMO 27
MARCO COSTA 27
ZHANG, XIAOXIA 23
LUO, TAO 21
KIM, SEUNGHWAN 19
SUN, JING 18
ZHANG, KAI 17
HU, JIE 16
TAO LUO 16
ZHANG, LI 16
NAGATA, SATOSHI 14
ZHOU, YAN 14
KHOSHNEVISAN, MOSTAFA 13
LIU, WENJUN 13
IPC code
G06F 2,170
A61K 1,581
H04L 1,348
H04W 1,164
H01L 1,141
G01N 874
A61B 861
G06Q 832
H04N 762
A61P 711
C12N 709
G06K 637
G06N 614
G06T 571
G02B 560
C07K 535
H01M 455
H04B 406
Publication Dates
2021 22,819
Kind code
A 12,223
A1 8,193
NPL 745
T3 216
U1 200
T5 102
B3 32
E1 21
A5 11
U 9
B4 7
T1 2

Settings


Feedback
Goto
Search
Browse
Tools
Settin
SETTINGS
Reset
Close
Save
Query
Office
Result
Interface
Others
Result List Language
Query Language
Result List View
All+Image
Analysis tab open
Analysis type
Table
Analysis graph
pie
No of Items/Group
50
Group by *
Countries
Offices
Applicants
Inventors
IPC code
CPC code
Publication Dates
Filing Dates
Kind code
Download Fields
Application Number
Application Date
Publication Numer
Publication Date
Country Code
Title
Abstract

How to search: NPL

- To select NPL as a field:
  - CTR: ZZ
  - DTY: NPL



How to search: keywords

- EN_AB: abstract of the article
- EN_TI: title of the article
- EN_DE: article



How to search: author, source, publisher & number

- AU: author of article
- JO: NPL source
- PN: number of the article
- PU: publisher



How to search: date and IPC

- IC: IPC codes
- DP: publication date

Example


ADVANCED SEARCH
EN_AB:asthma
Query Assistant
Query Examples
Expand with related terms
Offices
All
Languages
All
Stemming
Single Family Member
Include NPL
Reset
Search


EN_AB:asthma
296 results
Offices all
Languages all
Stemming true
Single Family Member false
Include NPL false
Sort: Relevance
Per page: 100
View: All+Image
1 / 323
Download
Machine translation
ANALYSIS
Close
Filters
Charts
Timeseries
Countries
China 7,072
United States of America 5,872
PCT 3,810
European Patent Office 3,090
Australia 2,239
Canada 2,114
Republic of Korea 1,200
New Zealand 1,050
Japan 1,033
India 894
Mexico 818
Russian Federation 533
Denmark 447
Malaysia 448
Non-Patent Literature 315
Offices
China 8,051
United States of America 6,994
PCT 3,810
European Patent Office 3,263
Canada 2,540
Australia 2,242
Republic of Korea 1,988
New Zealand 1,588
India 1,503
Japan 1,280
Mexico 1,109
Russian Federation 847
South Africa 509
Malaysia 457
Denmark 447
Applicants
ASTRAZENECA AB 654
SCHERING CO 481
MERCK AND CO INC 438
SMITHKLINE BEECHAM CO 408
NOVARTIS AG 373
GLAXO GROUP LIMITED 325
PFIZER INC 313
BOEHRINGER INGELHEIM INTERNATIONAL GMBH 295
F HOFFMANN LA ROCHE AG 285
JANSSEN PHARMACEUTICA NV 284
MERCK SHARP AND DOHME CO 268
BRISTOL MYERS SQUIBB COMPANY 258
ONO PHARMACEUTICAL CO LTD 257
Inventors
THE INVENTOR HAS WAIVED THE RIGHT TO BE MENTIONED 74
XIE YI 72
MAO YUMIN 70
RAY ABHIJIT 65
MARFAT ANTHONY 63
MACCOSS, MALCOLM 62
URBAHNS KLAUS 61
MARFAT, ANTHONY 58
KONRADI ANDREI W. 52
PLEISS MICHAEL A. 51
MAMMEN MATHAI 50
THORSETT, EUGENE D. 50
PLEISS, MICHAEL A. 49
RAY, ABHIJIT 49
COE DIANE MARY 47
IPC code
A61K 24,806
A61P 15,706
C07D 12,219
C07K 3,626
C07C 2,380
C12N 2,181
G01N 1,681
C12Q 1,173
A23L 982
C07H 835
A61M 749
C12P 683
A61B 603
A01N 492
C07F 323
Publication Dates
1972 15
1973 19
1974 21
1975 49
1976 58
1977 50
1979 31
1980 43
1981 59
1982 48
1983 42
1984 40
1985 78
1986 82
Kind code
A 15,107
A1 4,945
B2 3,078
B 2,598
B1 2,544
C 1,213
A4 508
NPL 315
C2 295
A2 288
C1 285
E 258
U 185
A3 183

1. **10.1038/NPJPCRM.2015.58** OBESITY, LOW LEVELS OF PHYSICAL ACTIVITY AND SMOKING PRESENT OPPORTUNITIES FOR PRIMARY CARE ASTHMA INTERVENTIONS: AN ANALYSIS OF BASELINE DATA FROM THE ASTHMA TOOLS STUDY — NPL - 01.10.2015

Int.Class A61B 5/00 **Publisher** nature **Journal** npj Primary Care Respiratory Medicine

Abstract Background: Asthma prevalence, severity and outcomes are associated with various patient characteristics and lifestyle choices. Aims: To identify potentially modifiable factors associated with poor asthma outcomes among US primary care patients. Methods: Using baseline data from the Asthma Tools Study, we calculated cross-sectional frequencies of activity levels, smoking, secondhand smoke exposure and the presence of obesity, as well as rates of out-of-control asthma and asthma exacerbations. Frequencies were stratified by sex, and into three age groups: 5–11 years, 12–18 years and 19 years and older. Logistic regression was used to identify factors associated with each of the asthma outcomes. Results: In the 901 individuals enrolled in this asthma study, tobacco smoke exposure, obesity, low activity levels, poverty, inadequately controlled asthma and high asthma-related health-care utilisation were common. Across all age groups, obesity was associated with poorer asthma outcomes: either poor asthma control [odds ratio (OR)=2.3, 95% confidence interval (CI) 1.1–4.7 in 5- to 11-year-olds and OR=1.5, 95% CI 1.1–2.2 in adults] or asthma exacerbations [OR 2.9, 95% CI 1.6–5.1 in 12- to 18-year-olds and OR 1.7, 95% CI 1.1–2.5 in adults]. Among adults, smoking was associated with both measures of poorer asthma outcomes; inadequate asthma control [OR=2.3, 95% CI 1.5–3.5], and asthma exacerbations [OR 1.7, 95% CI 1.1–2.6], and low physical activity were associated with poor asthma control [OR=1.5, 95% CI 1.1–2.2]. Conclusions: Obesity, low levels of physical activity and smoking are common, and they are associated with poor asthma outcomes in a sample of primary care patients, suggesting important targets for intervention.

2. **10.1038/S41533-018-0107-5** PROSPECTIVE OBSERVATIONAL COHORT STUDY OF SYMPTOM CONTROL PREDICTION IN PAEDIATRIC ASTHMA BY USING THE ROYAL COLLEGE OF PHYSICIANS THREE QUESTIONS — NPL - 24.10.2018

Int.Class A61B 5/00 **Publisher** nature **Journal** npj Primary Care Respiratory Medicine

Abstract The Royal College of Physicians three questions (RCP3Q) is widely used for assessing asthma control within primary care in the UK, despite limited evidence in children. This study compared the RCP3Q as a tool for assessing asthma control in children (5–16 years) against the validated Asthma Control Test (ACT), Childhood Asthma Control Test (C-ACT), and Mini-Paediatric Quality of Life Questionnaire (MiniPAQLQ). We conducted a prospective observational cohort study involving children from eight primary care practices in Leicestershire. Children with doctor diagnosed asthma, or receiving regular asthma medication, were invited to participate. A total of 319 participants completed the MiniPAQLQ and the C-ACT/ACT questionnaires, before RCP3Q responses were collected as part of their routine asthma review conducted immediately afterwards. RCP3Q sensitivity for detecting uncontrolled asthma ranged from 43–60% and specificity from 80–82%. Using an RCP3Q score ≥2 to predict uncontrolled asthma and an RCP3Q score of zero to predict well-controlled asthma resulted in 10% of participants misclassified as uncontrolled and 8% as well-controlled, respectively. Using an RCP3Q threshold score of ≥1 resulted in 25% of participants being misclassified as uncontrolled. Our data suggests limited utility of the RCP3Q to assess asthma control in children. Alternative indicators of asthma control, such as the validated Asthma Control Test and the Children's Asthma Control Test should be considered instead.

3. **10.1038/S41598-021-81022-Z** THE NATIONWIDE RETROSPECTIVE COHORT STUDY BY HEALTH INSURANCE REVIEW AND ASSESSMENT SERVICE PROVES THAT ASTHMA MANAGEMENT DECREASES THE EXACERBATION RISK OF ASTHMA — NPL - 14.01.2021

Int.Class G06Q 50/22 **Publisher** nature **Journal** Scientific Reports

Abstract Medical costs have recently increased in South Korea due to the rising rate of asthma. Primary clinics serve an important role in asthma management, as they are the first stop for patients presenting with symptoms. The Health Insurance Review and Assessment Service (HIRA) in South Korea has assessed asthma-management quality since 2013, but studies are lacking on whether these assessments have been performed properly and contribute toward reducing asthma exacerbations. Therefore, we investigated whether the HIRA's quality assessments have decreased asthma exacerbations using national health insurance claims data from 2013 to 2017 of 83,375 primary-clinic and 15,931 tertiary-hospital patients with asthma. These patients were classified into four groups based on disease severity according to the monthly prescribed amount of asthma medication using K-means clustering. The associations between HIRA assessments and asthma exacerbation were analyzed using a generalized estimating equation. Our results showed that exacerbation odds gradually decreased as the HIRA assessments progressed, especially in the mild-severity group, and that exacerbation risk among patients with asthma decreased in the order of assessment grades: "Unsatisfactory," "Satisfactory," and "Tertiary." Therefore, we may conclude that asthma exacerbations may decrease with high quality asthma management; appropriate quality assessment could be helpful in reducing asthma exacerbations.

4. **10.1038/S41533-017-0050-X** PERCEPTIONS OF ASTHMA CONTROL IN THE UNITED KINGDOM: A CROSS-SECTIONAL STUDY COMPARING PATIENT AND HEALTHCARE PROFESSIONALS' PERCEPTIONS OF ASTHMA CONTROL WITH VALIDATED ACT SCORES — NPL - 11.08.2017

Int.Class A61B 5/00 **Publisher** nature **Journal** npj Primary Care Respiratory Medicine

Abstract Perceptions of asthma control often vary between patients and physicians. This cross-sectional survey provided UK-specific data on actual and perceived asthma control in patients (18–75 years) attending routine asthma reviews in primary, secondary and tertiary settings. Differences between healthcare professionals' (HCP) and patients' perceptions of asthma control were evaluated via an online questionnaire and compared to a control—the validated asthma control test (ACT)—which patients completed. Treated patients (at least a short acting ß-agonist) with a documented diagnosis of asthma were enroled and consented within a month of their last appointment. Patients were grouped according to the British Thoracic Society (BTS)/Scottish Intercollegiate Guidelines Network (SIGN) 2014 treatment guidelines (BTS/SIGN steps 1–5). A total of 280 patients were screened: 234 were eligible for enrolment: 33, 52, 50, 49 and 50 patients in steps 1–5, respectively. Seventy per cent (164) were women. The percentage of patients aged 45–64 years was 47.4%. HCPs classed 70% (164) as non-smokers. 84.2% of patients and 73.9% of HCPs perceived that asthma was controlled but ACT results suggest that asthma was only controlled in 54.7% of patients (ACT score ≥20). Patients in steps 4 and 5 had the highest levels of uncontrolled asthma. Correct agreement between ACT score with perceptions of controlled or uncontrolled asthma occurred in 87.9% of patients and 68.8% of HCPs; the poorest levels of agreement occurred in patients in steps 4 and 5. Uncontrolled asthma is common in UK patients. High proportions of patients and HCPs have incorrect perceptions of asthma control, especially in relation to patients with asthma in steps 4 and 5.

5. **10.1038/S42003-020-01411-4** ALTERED TRANSCRIPTIONAL AND CHROMATIN RESPONSES TO RHINOVIRUS IN BRONCHIAL EPITHELIAL CELLS FROM ADULTS WITH ASTHMA — NPL - 13.11.2020

Int.Class C12Q 1/6883 **Publisher** nature **Journal** Communications Biology

1. NPL313168373 - OBESITY, LOW LEVELS OF PHYSICAL ACTIVITY AND SMOKING PRESENT OPPORTUNITIES FOR PRIMARY CARE ASTHMA INTERVENTIONS: AN ANALYSIS OF BASELINE DATA FROM THE ASTHMA TOOLS STUDY

NPL Biblio. Data | Description

PermaLink | Machine translation ▼

[EN]
Abstract

Abstract

Background:

Asthma prevalence, severity and outcomes are associated with various patient characteristics and lifestyle choices.

Aims:

To identify potentially modifiable factors associated with poor asthma outcomes among US primary care patients.

Methods:

Using baseline data from the Asthma Tools Study, we calculated cross-sectional frequencies of activity levels, smoking, secondhand smoke exposure and the presence of obesity, as well as rates of out-of-control asthma and asthma exacerbations. Frequencies were stratified by sex, and into three age groups: 5–11 years, 12–18 years and 19 years and older. Logistic regression was used to identify factors associated with each of the asthma outcomes.

Results:

In the 901 individuals enrolled in this asthma study, tobacco smoke exposure, obesity, low activity levels, poverty, inadequately controlled asthma and high asthma-related health-care utilisation were common. Across all age groups, obesity was associated with poorer asthma outcomes: either poor asthma control [odds ratio (OR)=2.3, 95% confidence interval (CI) 1.1–4.7 in 5- to 11-year-olds and OR=1.5, 95% CI 1.1–2.2 in adults] or asthma exacerbations [OR 2.9, 95% CI 1.6–5.1 in 12- to 18-year-olds and OR 1.7, 95% CI 1.1–2.5 in adults]. Among adults, smoking was associated with both measures of poorer asthma outcomes; inadequate asthma control [OR=2.3, 95% CI 1.5–3.5], and asthma exacerbations [OR 1.7, 95% CI 1.1–2.6], and low physical activity were associated with poor asthma control [OR=1.5, 95% CI 1.1–2.2].

Conclusions:

Obesity, low levels of physical activity and smoking are common, and they are associated with poor asthma outcomes in a sample of primary care patients, suggesting important targets for intervention.

Introduction

Asthma is common among US children and adults, with up to 1 in 8–11 children and 1 in 13 adults having received a physician diagnosis of asthma.[1,2] Asthma continues to be associated with a significant burden to patients, families and health-care systems.[3–6] That burden has been shown to be increased in certain age, sex, race/ethnicity and family income groups.[7–11] These commonly enumerated factors are seldom amenable to medical interventions.

However, asthma prevalence, severity and outcomes are also associated with several potentially modifiable patient characteristics and lifestyle choices including level of obesity,[12–14] smoking status,[15] levels of physical activity[16] and exposure to secondhand smoke.[8,17–20] Primary care physicians and practices provide the majority of asthma care[5] and are therefore appropriate sites in which to assess the frequency of the additional potentially modifiable characteristics and lifestyle choices, highlighting opportunities to use nonmedication-based interventions to improve asthma outcomes.

Families in PATENTSCOPE

- Step 1 - February 2020

PCT families:

- PCT application from which the family originated (IC1)
- National entry of a PCT application (IC2, IC3)
- Sole priority inside the family (IC5)

Families in PATENTSCOPE

- Step 2 - January 2021

PATENTSCOPE families = PCT + Paris routes

- Sole priority inside the family (IC5)
- US application related to another US application already included in the family (IC4)
- As per priority (IC6)

Codes summary

Codes	Definition
IC1	PCT application from which the family originated
IC2	National entry of a PCT application
IC3	National entry of a PCT application not found in PATENTSCOPE
IC4	US application related to another US application already included in the family
IC5	Sole priority inside the family
IC6	As per priority
IC7	National application related to another application of the same national office already included in the family

PATENTSCOPE families codes



Advanced search



Field Combination



Result list


IC:("A61K31/551")
25,523 results
Offices all
Languages all
Stemming true
Single Family Member false
Include NPL false
REFINE OPTIONS
Close
Search
Offices
All
Languages
All
Stemming
Single Family Member
Include NPL



Markush search: 1



CHEMICAL COMPOUNDS SEARCH

Convert structure | Upload structure | Structure editor | Found compounds | Found Markush Formulas

Search type
Compound name

Type an accepted name, commercial name, CAS name, IUPAC name
cimetidine

☐ Search for scaffold

☑ Include enumerated Markush structures

Offices
All

Reset | Show in editor | **Exact Structure Search**

CHEM:(AQIXAKUUQRKLND-UHFFFAOYSA-N) OR ENUM:(AQIXAKUUQRKLND-UHFFFAOYSA-N)

28,070 results Offices all Languages all Stemming true Single Family Member false Include NPL false

Sort: Relevance Per page: 100 View: All+Image 1 / 281 Download Machine translation

1. **0560937** PHARMACEUTICAL COMPOSITIONS — EP - 22.09.1993

Int.Class A61K 9/16 **Appl.No** 92903167 **Applicant** SMITHKLINE BEECHAM CORP **Inventor** MARSHALL KEITH

The present invention provides for a phased-release oral dosage form comprising a plurality of H¿2? receptor antagonist pellets in a polymer matrix. Each phase, containing a plurality of pellets which may be optionally coated with a release delaying substance, may have different release rates, thereby providing release of the H¿2? antagonist over an extended duration of time.

2. **0650353** PALATABLE PHARMACEUTICAL COMPOSITIONS — EP - 03.05.1995

Int.Class A61K 9/00 **Appl.No** 93914418 **Applicant** SMITHKLINE BEECHAM CORP **Inventor** BHARDWAJ SANJAY

A pharmaceutical granular composition and method for taste masking bitter, unpleasant tasting drugs comprising a drug core and as a taste masking agent methacrylate ester copolymers. The method comprises coating the drug cores with separate layers of aqueous dispersions of the copolymers. Additionally, the coating composition may contain plasticizers and conventional excipients. The granules of the present invention can be used in the preparation of chewable tablets which have good palatability and bioavailability. Preferable copolymers are poly[ethylacrylate, methylmethacrylate] to which quaternary ammonium groups have been introduced to modify the permeability of the ester. The coating sytem of this invention releases the drug by diffusion and is influenced by drug solubility and media pH.

3. **0347767** DISPERSIBLE CIMETIDINE TABLETS — EP - 27.12.1989

Int.Class A61K 9/20 **Appl.No** 89110951 **Applicant** LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, D.D. **Inventor** KOVACIC, MATEJA

There are described novel dispersible cimetidine tablets containing 30 to 90 % by weight of one of the polymorphous modifications of cimetidine A, B or C, 5 to 55 % by weight of one or more disintegrationg agents, 0.05 to 5.0 % by weight of a surfactant, such as sodium lauryl sulphate together with other common adjuvants. The process for the manufacture of dispersible cimetidine tablets is effected on the basis of known methods by granulating the ingredients and by compressing the granulate to tablets. Dispersible tablets disintegrate when brought in contact with water at room temperature within less than 1 minute to yield a fine dispersion, which facilitates the oral application. Therefore such tablets are particularly suitable for certain groups of patients, especiallly for the aged and children. Dispersible tablets containing cimetidine excell by their improved rate of dissolution and good bioavailability



Advantages

- Simplicity
- Response times
- Combination with other fields

ENUM:(AQIXAKUUQRKLND-UHFFFAOYSA-N) AND EN_AB:(gastric OR gastro)

75 results Offices all Languages all Stemming true Single Family Member false Include NPL false

Sort: Relevance Per page: 100 View: All+Image 1 / 1 Download Machine translation

1. **0108452** TREATMENT OF GASTRIC INFLAMMATORY DISEASE WITH CYTOPROTECTIVE PROSTAGLANDINS AND HISTAMINE-2 BLOCKING ANTI-SECRETORY AGENTS. EP - 16.05.1984

Int.Class A61K 31/415 Appl.No 83201551 Applicant PROCTER & GAMBLE Inventor WAGNER GREGORY STEVEN

Compositions comprising gastric cytoprotective prostaglandin or prostaglandin-like compounds and histamine-2 receptor blocking anti-secretory agents useful in the treatment and prophylaxis of gastric inflammatory conditions are disclosed. These compositions are effective in the treatment and prophylaxis of gastro-intestinal ulceration. They utilize levels of both prostaglandin and anti-secretory agents which are significantly lower than ordinarily required as the prostaglandin potentiates the effect of the anti-secretory agent, and minimizes the side effects which are frequently associated with the administration of prostaglandins. The method of treating and preventing gastric inflammatory diseases using these compositions is also disclosed.

2. **1209044** TREATMENT OF GASTRIC INFLAMMATORY DISEASE WITH CYTOPROTECTIVE PROSTAGLANDINS AND HISTAMIN-2 RECEPTOR BLOCKING ANTI-SECRETORY AGENTS CA - 05.08.1986

Int.Class A61K 31/557 Appl.No 440524 Applicant Inventor WAGNER, GREGORY S.

TREATMENT OF GASTRIC INFLAMMATORY DISEASE WITH CYTOPROTECTIVE PROSTAGLANDINS AND HISTAMINE-2 RECEPTOR BLOCKING ANTI-SECRETORY AGENTS ABSTRACT Compositions comprising gastric cytoprotective prostaglandin or prostaglandin-like compounds and histamine-2 receptor blocking anti-secretory agents useful in the treatment and prophylaxis of gastric inflammatory conditions are disclosed. These compositions are effective in the treatment and prophylaxis of gastro-intestinal ulceration. They utilize levels of both prostaglandin and anti-sec- retory agents which are significantly lower than ordinarily required as the prostaglandin potentiates the effect of the anti-secretory agent, and minimizes the side effects which are frequently associ- ated with the administration of prostaglandins. The method of treating and preventing gastric inflammatory diseases using these compositions is also disclosed.



3. **0814773** PECTIN LIQUID PHARMACEUTICAL COMPOSITIONS EP - 07.01.1998

Int.Class A61K 9/00 Appl.No 96908089 Applicant BOOTS CO PLC Inventor COX GILLIAN

The invention relates to a liquid composition for use in the prevention of gastric reflux, the composition comprising: a pectin gel raft-forming agent; a pectin, or a pharmaceutically acceptable salt thereof; a pharmaceutically acceptable metal ion component; one or more substances capable of producing a pharmaceutically acceptable gas at the physiological pH normally present in the stomach; the composition forming a gel raft in a gastric environment; in which the metal ion component is coated with a material to prevent the composition from forming a gel raft in a non-gastric environment. Preferably the composition further comprising one or more additional ingredients selected from: one or more antacid agents, one or more antibiotics, one or more anti-cholinergic agents, one or more anti-emetic agents, one or more cytoprotectants, one or more H¿2? receptor antagonists, one or more local anaesthetics, one or more proton pump inhibitors and any suitable and compatible mixtures thereof.

Disadvantages

- Limited recall
- Only exact compound

Markush search: 2



CHEMICAL COMPOUNDS SEARCH

Convert structure | Upload structure | Structure editor | Found compounds | Found Markush Formulas

Search for scaffold

Include enumerated Markush structures

Offices


Feedback
Goto
Search
Browse
Tools
Settings
CHEMICAL COMPOUNDS SEARCH
Convert structure
Upload structure
Structure editor
Found compounds
Found Markush Formulas
Search type
Compound name
Type an accepted name, commercial name, CAS name, IUPAC name
lansoprazole
Search for scaffold
Include enumerated Markush structures
Offices
All
Reset
Show in editor
Exact Structure Search



InChI: InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11

InChiKey: MJIHNNLFOKEZEW-UHFFFAOYSA-N

Molecular Formula: C16H14F3N3O2S

Molecular Weight: 369.3664 g/mol

Search for scaffold

Include enumerated Markush structures

Offices

All

Fuzzy and ranked substructure Search

Fuzzy substructure Search

Substructure Search

Exact Search

Reset | Markush Search | Substructure Search | Exact Structure Search | Evaluate


CHEMICAL COMPOUNDS SEARCH
Convert structure
Upload structure
Structure editor
Found compounds
Found Markush Formulas
search results [0 hits found, 2.62% searched]
Sort by natural
[1 of 1]
1
24
Show more...
[1 of 1]
1
24
Markush search results [0 hits found, 2.62% searched]
Offices
All
Reset
Clear all
Select all
Search
Batch

[1 of 1] 1 24

9117-08201



9138-09401



8238-69401



9734-40901



0016-85501



0039-53701



0040-03901



0054-75003



0087-15801



0132-17102



1070-61601



Show more...

[1 of 1] 1 24

Markush search result (11 hits found, 69.96% searched)

Offices
All

Reset | Clear all | Select all | **Search** | Batch


MN:(9117-08201^5 OR 9138-09401^5 OR 8238-69401^5 OR 9734-40901^5 OR 0016-85501^5 OR 0039-53701^5 OR 0040-03901^5 OR 0054-75003^5 OR 0087-15801^5 OR 0132-17102^5 OR 1070-61(
Sort: Relevance
MN:(9117-08201^5 OR 9138-09401^5 OR 8238-69401^5 OR 9734-40901^5 OR 0016-85501^5 OR 0039-53701^5 OR 0040-03901^5 OR 0054-75003^5 OR 0087-15801^5 OR 0132-17102^5 OR 1070-61(
87 results Offices all Languages all Stemming true Single Family Member false Include NPL false
FULL QUERY
Close
Edit
MN:(9117-08201^5 OR 9138-09401^5 OR 8238-69401^5 OR 9734-40901^5 OR 0016-85501^5 OR 0039-53701^5 OR 0040-03901^5 OR 0054-75003^5 OR 0087-15801^5 OR 0132-17102^5 OR 1070-61601^5 OR null)
1. 0446961
Int.Class A61K 9
The pharmaceuti
carbamoylalkyl,
dialkylcarbamoyl
may optionally b
1991
2. 0423748 STABILIZED PHARMACEUTICAL COMPOSITION AND ITS PRODUCTION.
EP - 24.04.1991
Int.Class A61K 9/16 Appl.No 90119891 Applicant TAKEDA CHEMICAL INDUSTRIES LTD Inventor MAKINO TADASHI
The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula wherein R<1> is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R<2> is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R<3> and R<5> are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R<4> is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt of magnesium and/or a basic inorganic salt of calcium, is physically stable.
NO IMAGE AVAILABLE
3. 000003750431 STABILISIERTES ARZNEIMITTEL UND DESSEN HERSTELLUNG.
DE - 22.12.1994
Int.Class A61K 31/44 Appl.No 3750431 Applicant TAKEDA CHEMICAL INDUSTRIES LTD Inventor HIRAI SHIN-ICHIRO
NO IMAGE

1. EP0446961 - STABILIZED PHARMACEUTICAL COMPOSITION AND ITS PRODUCTION

National Biblio. Data | Description | Claims | Patent Family | Compounds | Markush | Documents

PermaLink

Markush Nr.	Markush formula
9138-09401	

Enumerated compounds

Note: These structures have been created automatically. Please use the original Markush definition in the PDF version for legal matters

1 2 3 4 5 6 7 8 9 10

HBDKFZNDMVLSHM-UHFFFAOYSA-N



ZFUVBCOUKXFRIG-UHFFFAOYSA-N



ZFUVBCOUKXFRIG-UHFFFAOYSA-N



BQSRNAUDMPQYKZ-UHFFFAOYSA-N



SOMRZJSTDCVDES-UHFFFAOYSA-N



SOMRZJSTDCVDES-UHFFFAOYSA-N



NJJRWERALDFUMA-UHFFFAOYSA-N



LEPJWVYZVKEIPB-UHFFFAOYSA-N



LEPJWVYZVKEIPB-UHFFFAOYSA-N



MSVPDUIRKKWSDW-UHFFFAOYSA-N



YNRXQBPXUVQHBZ-UHFFFAOYSA-N



YNRXQBPXUVQHBZ-UHFFFAOYSA-N



Advantages

- Recall
- Search scope
- Search options

Disadvantages

- Long response times
- Complex
- No repeating group

FAQs

- Where to find help? User's Guide in *Help* menu
- Coverage? IP5 and & the published PCT applications
- Comparison with other tools? None
- Future improvements? Response times

Tips & tricks videos





Summer practical sessions

New collections added

- Finland
- New Zealand
- Kazakhstan
- Poland

1-click access to doc in national databases

1. CA1332322 - DROP END, OPEN TOP RAIL CAR

National Biblio. Data | Description | Claims | Drawings | Patent Family | Documents

PermaLink | Machine translation

Office
Canada

Application Number
612053

Application Date
20.09.1989

Publication Number
1332322

Publication Date
11.10.1994

Grant Number

Grant Date
11.10.1994

Publication Kind
C

IPC
B61D 9/02 | B61D 3/18 | B61D 17/06 | B61F 1/10

CPC
B61D 3/187 | B61F 1/10

Inventors
MURRAY, JOHN RYLEN, JR.

Title
(EN) DROP END, OPEN TOP RAIL CAR
(FR) WAGON DECOUVERT A BOUTS RABATTABLES



Abstract
(EN) ABSTRACT OF THE DISCLOSURE There is disclosed a drop end for a railway car which is adapted to be manipulated [lifted] from within the car by power equipment to open or close the car end. The car end includes lower side posts, each having a cam follower running in a cam on the car frame which swings the car end when lifted. The car end is swung about a pivot carried on the posts which are guided in a vertical slot cam that cooperates with the swing cam. The car end is opened outwardly of the car and rests in open horizontal position on a pedestal support of the frame so that adjacent open car ends form a bridge to

ECTUAL PROPERTY
ZATION

Canadian Patents Database

- Introduction
- Green Technologies
- Search
  - Basic Search
  - Number Search
  - Boolean Search
  - Advanced Search
- Help
  - General Content
  - Searching
  - Search Language
  - FAQ
- Disclaimer

Patent 1332322 Summary

▸ Third-party information liability

▸ Claims and Abstract availability

(12) Patent:	(11) CA 1332322
(21) Application Number:	612053
(54) English Title:	DROP END, OPEN TOP RAIL CAR
(54) French Title:	WAGON DECOUVERT A BOUTS RABATTABLES

▼ Bibliographic Data

(52) Canadian Patent Classification (CPC):	105/115
(51) International Patent Classification (IPC):	*B61D 9/02* (2006.01) *B61D 3/18* (2006.01) *B61D 17/06* (2006.01) *B61F 1/10* (2006.01)
(72) Inventors :	**FLOWERS, RICHARD W.** (United States of America) **MURRAY, JOHN RYLEN, JR.** (United States of America)
(73) Owners :	**DIFCO, INC.** (United States of America)
(71) Applicants :	
(74) Agent:	**GOWLING WLG (CANADA) LLP**
(74) Associate agent:	
(45) Issued:	**1994-10-11**
(22) Filed Date:	**1989-09-20**
Availability of licence:	**N/A**
(25) Language of filing:	**English**

Patent Cooperation Treaty (PCT):	No

(30) Application Priority Data:

Application No.	Country/Territory	Date

1. US20210344887 - DYNAMIC VIBRATION SENSOR OPTICS DISTORTION PREDICTION

National Biblio. Data | Description | Claims | Drawings | Patent Family | Documents

PermaLink | Machine translation

Office
United States of America

Application Number
16863124

Application Date
30.04.2020

Publication Number
20210344887

Publication Date
04.11.2021

Grant Number
11166003

Grant Date
02.11.2021

Publication Kind
B1

IPC
H04N 13/128 | H04N 5/225 | G06T 5/00 | G06T 5/50 | B60R 11/04

CPC

Title
[EN] DYNAMIC VIBRATION SENSOR OPTICS DISTORTION PREDICTION



Abstract
[EN]
The present disclosure discloses a system and a method for mitigating image distortion. In an example implementation, the system and the method can receive vehicle state data and vehicle inertial measurement data; generate an image distortion prediction indicative of image distortion within an image captured by

United States Patent Application ***20210344887***
Kind Code **A1**
Herman; David Michael ; et al. **November 4, 2021**

DYNAMIC VIBRATION SENSOR OPTICS DISTORTION PREDICTION

Abstract

The present disclosure discloses a system and a method for mitigating image distortion. In an example implementation, the system and the method can receive vehicle state data and vehicle inertial measurement data; generate an image distortion prediction indicative of image distortion within an image captured by the image capture assembly based on the vehicle state data and the vehicle inertial measurement data; and at least one of correct or mitigate the image distortion based on the image distortion prediction.

Inventors: **Herman; David Michael**; *(Oak Park, MI)* ; **Lesky; Aaron**; *(Ypsilanti, MI)* ; **Beras; Ronald**; *(Warren, MI)*

Applicant:

Name	City	State	Country	Type
Ford Global Technologies, LLC	Dearborn	MI	US	

Assignee: **Ford Global Technologies, LLC**
Dearborn
MI

Family ID: **78243122**
Appl. No.: **16/863124**
Filed: **April 30, 2020**

Current U.S. Class: **1/1**
Current CPC Class: G06T 2207/10012 20130101; H04N 2013/0096 20130101; G06T 5/006 20130101; H04N 13/128 20180501; B60R 11/04 20130101; G06T 2207/30252 20130101; B60R 2011/004 20130101; H04N 5/2252 20130101; G06T 5/50 20130101; H04N 2013/0081 20130101
International Class: H04N 13/128 20060101 H04N013/128; H04N 5/225 20060101 H04N005/225; G06T 5/00 20060101 G06T005/00; G06T 5/50 20060101 G06T005/50; B60R 11/04 20060101 B60R011/04

Claims

US 20210344887A1

(19) **United States**

(12) **Patent Application Publication**

Herman et al.

(10) **Pub. No.: US 2021/0344887 A1**

(43) **Pub. Date: Nov. 4, 2021**

(54) **DYNAMIC VIBRATION SENSOR OPTICS DISTORTION PREDICTION**

(71) Applicant: **Ford Global Technologies, LLC**, Dearborn, MI (US)

(72) Inventors: **David Michael Herman**, Oak Park, MI (US); **Aaron Lesky**, Ypsilanti, MI (US); **Ronald Beras**, Warren, MI (US)

(73) Assignee: **Ford Global Technologies, LLC**, Dearborn, MI (US)

(21) Appl. No.: **16/863,124**

(22) Filed: **Apr. 30, 2020**

Publication Classification

(51) **Int. Cl.**

H04N 13/128	(2006.01)
H04N 5/225	(2006.01)
G06T 5/00	(2006.01)
G06T 5/50	(2006.01)
B60R 11/04	(2006.01)

(52) **U.S. Cl.**

CPC ***H04N 13/128*** (2018.05); ***H04N 5/2252*** (2013.01); *H04N 2013/0096* (2013.01); ***G06T 5/50*** (2013.01); ***B60R 11/04*** (2013.01); ***G06T 5/006*** (2013.01)

(57) **ABSTRACT**

The present disclosure discloses a system and a method for mitigating image distortion. In an example implementation, the system and the method can receive vehicle state data and vehicle inertial measurement data; generate an image distortion prediction indicative of image distortion within an image captured by the image capture assembly based on the vehicle state data and the vehicle inertial measurement data; and at least one of correct or mitigate the image distortion based on the image distortion prediction.



2022

- More national collections
- More NPL
- Improve families with PCT member
- Certification of authority files
- Integration of f terms search
- Online practical exercises platform – looking for pilot tester


Webinar

Future/past webinars: wipo.int/patentscope/en/webinar



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

Next webinar

- In 2022!
  - Tuesday session at 5:30 pm CET
  - Thursday session at 8:30am CET

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

Global Brand Database, Global Design Database

Webinars:

- https://www.wipo.int/reference/en/branddb/webinar/index.html
- https://www.wipo.int/reference/en/designdb/webinar/index.html

HAPPY HOLIDAY SEASON

patentscope@wipo.int